Trastuzumab sensitivity of breast cancer with co-amplification of HER2 and cMYC suggests pro-apoptotic function of dysregulated cMYC in vivo

被引：0
|
作者：
Kim, C. [1 ]
Bryant, J. [1 ]
Horne, Z. [1 ]
Geyer, C. E. [1 ]
Wickerham, D. L. [1 ]
Wolmark, N. [1 ]
Paik, S. [1 ]
机构：
[1] NSABP Operat & Biostat Ctr, Pittsburgh, PA USA
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2006年 / 100卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：340 / 341
页数：2
相关论文
共 50 条
  • [41] HER2 amplification level by in situ hybridization predicts survival outcome in advanced HER2-positive breast cancer treated with pertuzumab, trastuzumab, and docetaxel regardless of HER2 IHC results
    Seo, Jeongmin
    Koh, Jiwon
    Lee, Dae-Won
    Kim, Jinyong
    Ryu, Han Suk
    Lee, Kyung-Hun
    Kim, Tae-Yong
    Im, Seock-Ah
    BREAST CANCER RESEARCH, 2023, 25 (01)
  • [42] HER2 amplification level by in situ hybridization predicts survival outcome in advanced HER2-positive breast cancer treated with pertuzumab, trastuzumab, and docetaxel regardless of HER2 IHC results
    Jeongmin Seo
    Jiwon Koh
    Dae-Won Lee
    Jinyong Kim
    Han Suk Ryu
    Kyung-Hun Lee
    Tae-Yong Kim
    Seock-Ah Im
    Breast Cancer Research, 25
  • [43] Atypical Co-amplification with Co-localization of HER2 Gene in Breast Cancer: Combined IHC/FISH Approach as per ASCO/CAP 2018 Guidelines for Targeted Therapy Eligibility
    Ushang Kate
    Anurita Pais
    Neelam Kamble
    Sandhya Kandoor
    Kunal Sharma
    Indian Journal of Surgical Oncology, 2024, 15 : 8 - 11
  • [44] Long term effects of trastuzumab on cardiopulmonary and left ventricular function in women with HER2 overexpressing breast cancer
    Pituskin, E.
    Paterson, I.
    Ghosh, S.
    Mackey, J. R.
    Haykowsky, M. J.
    CANCER RESEARCH, 2016, 76
  • [45] In vivo inhibition of metastatic HER2 positive trastuzumab resistant breast cancer using engineered destabilized 3UTR ARE of HER2 improves survival outcomes
    Awah, Chidiebere U.
    Mun, Joo Sun
    Boylu, Baris
    Paragodaarachchi, Alooka
    Ochu, Chika
    Matsui, Hiroshi
    Ogunwobi, Olorunseun O.
    CANCER RESEARCH, 2023, 83 (07)
  • [46] Inhibition of CXCR4 pathway augments trastuzumab sensitivity in HER2 positive breast cancer cells with intrinsic and acquired trastuzumab resistance
    Mehta, Arjun
    Yang-Kolodji, Gloria
    Tripathy, Debu
    CANCER RESEARCH, 2014, 74 (19)
  • [47] Evaluation of pro-apoptotic BIM gene loss of function on lapatinib efficacy in patients with metastatic breast cancer (MBC) and in HER2-amplified cell lines
    Spraggs, Colin F.
    Briley, Linda P.
    King, Karen S.
    Zhou, Felix
    Qin, Sherry
    Qin, Crystal Ying
    Russo, Mark W.
    Parham, Laura Rae
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [48] Tumor uptake of 64Cu-DOTA-trastuzumab correlates with HER2 gene amplification in patients with metastatic breast cancer
    Bading, James
    Press, Michael
    Villalobos, Ivonne
    Frankel, Paul
    Park, Jinha
    Tran, Tri
    Carroll, Mary
    Poku, Erasmus
    Miles, Joshua
    Colcher, David
    Mortimer, Joanne
    JOURNAL OF NUCLEAR MEDICINE, 2016, 57
  • [49] miR-125a Induces HER2 Expression and Sensitivity to Trastuzumab in Triple-Negative Breast Cancer Lines
    Ninio-Many, Lihi
    Hikri, Elad
    Burg-Golani, Tamar
    Stemmer, Salomon M.
    Shalgi, Ruth
    Ben-Aharon, Irit
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [50] Effect of TOP2A and cMYC gene copy number on outcome in a Phase II trial of adjuvant TC (Docetaxel/Cyclophosphamide) plus trastuzumab (HER TC) in HER2-positive early stage breast cancer
    Jones, S.
    Collea, R.
    Paul, D.
    Sedlacek, S.
    Favret, A.
    Gore, I.
    Lindquist, D. L.
    Holmes, F. A.
    Allison, M. A. K.
    Steinberg, M. S.
    Stokoe, C.
    Portillo, R. M.
    Crockett, M.
    Wang, Y.
    Lina, A.
    Robert, N. J.
    O'Shaughnessy, J.
    CANCER RESEARCH, 2012, 72
12345